Exercise-boosted donor immune cells to prevent leukemia relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving donor immune cells after a stem cell transplant can help prevent leukemia from coming back. The donor will do exercise sessions before donating cells to potentially make the treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 0 and 65 years old
- You have acute leukemia, myelodysplastic syndrome (a bone marrow disorder), chronic myeloid leukemia, or non-Hodgkin's lymphoma
- You have had or will have a stem cell transplant from a matched sibling or a half-matched family donor
- You have a healthy donor between 12 and 50 years old who can exercise and is willing to participate
- You do not have severe graft-versus-host disease (donor cells attacking your body) or need strong immune-suppressing drugs for it
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether giving extra donor immune cells (called DLI) after a stem cell transplant can help prevent relapse in people with hard-to-treat myeloid cancers. It may be an option if you had active disease at transplant but then achieved a deep remission.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Hear when a new Acute Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.